CompletedNot applicableNCT00038675

Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate

Studying Hypereosinophilic syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
M.D. Anderson Cancer Center
Principal Investigator
Jorge Cortes, MD
UT MD Anderson Cancer Center
Intervention
Imatinib Mesylate (Gleevec)(drug)
Enrollment
125 enrolled
Eligibility
All sexes
Timeline
20012013

Study locations (1)

Collaborators

Novartis Pharmaceuticals

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00038675 on ClinicalTrials.gov

Other trials for Hypereosinophilic syndrome

Additional recruiting or active studies for the same condition.

See all trials for Hypereosinophilic syndrome

← Back to all trials